Full Press Release Details
Cellectar to Participate
in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 8, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the
discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company
overview and be available for 1x1 meetings at the following upcoming conference:
2021 Virtual Healthcare Conference
Presentation Date: July
Presentation Time: 3:00
Webcast Link: https://wsw.com/webcast/ladenburg7/clrb/2395361
A replay of the presentation
will be available on the Events Page of the company's website (www.cellectar.com).
About Cellectar Biosciences, Inc.
Cellectar Biosciences
is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently
and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug
Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better
safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development
The company's product
pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is currently enrolling in a global, pivotal Phase 2 Part
B (CLOVER-WaM) expansion trial in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy,
including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The WM trial will enroll up to 50 patients to evaluate
the efficacy and safety of CLR 131 for marketing approval.
For more information,
please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company's
social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
This news release contains
forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe,"
"anticipate," "intend," "could," "estimate," "continue," "plans," or their
negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to any potential disruptions at our sole source supplier of
CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical
development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation,
our ability to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is
contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December
31, 2020. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking